ProQR Therapeutics (PRQR) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRQR shares.
View PRQR analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued 12-month price targets for ProQR Therapeutics' stock. Their PRQR share price forecasts range from $2.25 to $5.00. On average, they anticipate the company's share price to reach $4.35 in the next twelve months. This suggests a possible upside of 135.1% from the stock's current price.
View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts.

ProQR Therapeutics' stock was trading at $3.70 at the start of the year. Since then, PRQR stock has decreased by 50.0% and is now trading at $1.85.
View the best growth stocks for 2023 here.

ProQR Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 1,370,000 shares, a decline of 33.5% from the April 30th total of 2,060,000 shares. Based on an average daily volume of 871,000 shares, the short-interest ratio is presently 1.6 days. Approximately 2.5% of the shares of the stock are short sold.
View ProQR Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PRQR earnings forecast.

ProQR Therapeutics (NASDAQ:PRQR) released its quarterly earnings data on Wednesday, March, 29th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.04. The biopharmaceutical company had revenue of $0.84 million for the quarter, compared to the consensus estimate of $1 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 84.97% and a negative net margin of 1,707.31%.

Direxion mRNA ETF holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

ProQR Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (3.59%), Two Sigma Investments LP (0.52%), Two Sigma Advisers LP (0.46%), JPMorgan Chase & Co. (0.28%), HRT Financial LP (0.21%) and Bank of America Corp DE (0.19%).

Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRQR stock can currently be purchased for approximately $1.85.

ProQR Therapeutics (NASDAQ:PRQR) has a market capitalization of $149.52 million and generates $4.25 million in revenue each year. The biopharmaceutical company earns $-68,600,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

The company employs 1,504 workers across the globe.

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The official website for the company is www.proqr.com. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at ir@proqr.com.